Phytopharm plc is a development stage pharmaceutical Group developing novel treatments targeting diseases with high levels of unmet need, with the objective of developing products to key value inflection
points before seeking late-stage development and/or commercial partners, as appropriate.

Phytopharm operates as a virtual Group ensuring the majority of our financial resources are focussed on the development our pharmaceutical pipeline. We utilise a network of external scientific and clinical experts to help
guide our development programmes with our experienced pharmaceutical managers overseeing operations.

Phytopharm shares are included on the Premium Segment of the official list of the UKLA and are traded on the London Stock Exchange main market (Symbol: PYM).